University of Minnesota. Driven to Discover.
Vaccine mistrust after problems with the launch of Dengvaxia is one factor fueling the Philippines' outbreak.
A total of 62.4% of patients taking tafenoquine were free of P vivax after 6 months.
The findings add to the conundrum that governments face, as the vaccine prevents hospital stays in children who have antibodies to the dengue virus.
The controversial dengue vaccine should not be used until clinicians can confirm prior dengue infection, and such a test is at least 2 years away.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.